China
Africa
Explore chapters and articles related to this topic
Sexuality and Sexual Dysfunction
Published in Jane M. Ussher, Joan C. Chrisler, Janette Perz, Routledge International Handbook of Women’s Sexual and Reproductive Health, 2019
Flibanserin, which has pharmacological effects on serotonin and dopamine receptors (Borsini et al., 2002), is the first drug approved by the U.S. Food and Drug Administration for the treatment of female sexual dysfunction (Gellad, Flynn, & Alexander, 2015). While flibanserin was being tested on patients with Major Depressive Disorder, the positive effect of this drug on women’s sexual functioning was discovered (Stahl, Sommer, & Allers, 2011). Even though it was ineffective as an antidepressant, it improved sexual functioning in women with depression (Kennedy, 2010). Research suggests that some women with Hypoactive Sexual Desire Disorder can benefit from flibanserin (Katz et al., 2013; Thorp et al., 2012), but the drug has been criticized for its modest effectiveness and an increased risk of hypotension and syncope when used with alcohol (Brotto, 2015).
Physical Treatments for Sexual Problems
Published in Philipa A Brough, Margaret Denman, Introduction to Psychosexual Medicine, 2019
Flibanserin is a centrally-acting agent licenced in the United States 2 years ago for the treatment of female sexual interest/arousal disorder (FSIAD) in pre-menopausal women. More recent studies have also shown some evidence for efficacy in treating hypoactive sexual desire disorder in post-menopausal women (16). However, studies into this and other newer agents such as bremelanotide are sponsored by the pharmaceutical industry, and there has been controversy in the United States about the awarding of the US Food and Drug Administration licence.
Expanding medicine
Published in Kevin Dew, Public Health, Personal Health and Pills, 2018
The development of drugs to maintain or enhance sexual performance in ageing bodies has been popularly embraced. For men, this has been evident for some years with the success of drugs like Viagra, which was approved by the FDA in 1998. For women, developments have been more recent with drug companies successfully lobbying for a condition of female hypoactive desire disorder to be recognised so that a potential treatment for this condition, a drug called Flibanserin, could be marketed. Flibanserin was approved in 2015. The development of drugs to enhance sexual performance are, according to Barbara Marshall, revising standards of sexual functioning, with active sexuality becoming a marker of successful ageing (Marshall 2010).
The yin and yang of GSM and low sexual desire
Published in Climacteric, 2023
S. A. Kingsberg, B. Adler, J. Metropoulos, S. S. Faubion
Two prescription therapies are approved for the use of HSDD in the USA, flibanserin and bremelanotide. Flibanserin [33], a non-hormonal treatment, was US Food and Drug Administration (FDA) approved in 2015 for the treatment of premenopausal women with acquired, generalized, HSDD. It was approved in Canada in 2018 for use in women up to the age of 60 years. Flibanserin is a mixed serotonin agonist and antagonist that is hypothesized to raise dopamine and decrease post-synaptic serotonin [34]. Common side effects of flibanserin include dizziness, somnolence, headache and nausea. When used with alcohol, flibanserin can result in low blood pressure and syncope. Clinicians should counsel patients to wait at least 2 h after consuming alcohol to take flibanserin [33]. Of note, a recent post-hoc analysis found that the use of flibanserin was associated with weight loss [35].
A Randomized, Waiting-List-Controlled Study Shows That Brief, Mindfulness-Based Psychological Interventions Are Effective for Treatment of Women’s Low Sexual Desire
Published in The Journal of Sex Research, 2019
Annika Gunst, Daniel Ventus, Stefan Arver, Cecilia Dhejne, Katarina Görts-Öberg, Elin Zamore-Söderström, Patrick Jern
A large number of pharmacological treatments have been evaluated in the treatment of low sexual desire in women (Brotto, 2017), with one drug, flibanserin, approved by the U.S. Food and Drug Administration and Health Canada for treatment of low sexual desire in premenopausal women. However, flibanserin has a disputable clinical effect, and side effects such as dizziness and nausea are frequently reported (Jaspers et al., 2016). In recent years, there has been renewed scientific interest in psychological treatment for female sexual dysfunctions (Brotto, 2017). Although promising, at present only a few randomized controlled studies of psychological treatments for low sexual desire in women have been published, and the treatment effects and methodological quality of these studies vary considerably.
Efficacy of Tribulus Terrestris for the treatment of premenopausal women with hypoactive sexual desire disorder: a randomized double-blinded, placebo-controlled trial
Published in Gynecological Endocrinology, 2018
Fabiene Bernardes Castro Vale, Karla Zanolla Dias de Souza, Camilla Russi Rezende, Selmo Geber
Although several approaches to the management of this medical condition have been suggested, currently only the Flibanserin is licensed for the pharmacological treatments for premenopausal women diagnosed with HSDD [9]. Flibanserin can be prescribed to premenopausal women aged 18 years or higher who has regular menstrual cycle, but it is contraindicated for women with compromised liver function, breast-feeding and alcohol users. Also, its administration with fluconazole, ketoconazole, SSRI/SNRI, hormonal contraceptives, triptans, herb extracts and several other drugs requiring no doctor prescription is prohibited because it is likely to increase the risk of adverse effects [10]. The most common side effects were depression of the central nervous system, fatigue, drowsiness and vertigo [11].